Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07199335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Study acronym: ASCEND
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary and study completion dates: Sep 2027 to Dec 2028 · Start date changed from estimate of Nov 2025 to Feb 24, 2026 · Site details revised at 2 of 2 sitesv3 Show 3 more changesShow less
    • Primary and study completion dates: Sep 2027 to Dec 2028
    • Start date changed from estimate of Nov 2025 to Feb 24, 2026
    • Site details revised at 2 of 2 sites
  2. Study description revised Study title shortened, about 8 wordsv2 Show 1 more changeShow less
    • Study title shortened, about 8 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to determine the feasibility and impact of delivering long-acting injectable cabotegravir HIV pre-exposure prophylaxis and suite of support services to adults who inject non-prescription drugs who are risk for HIV through known sexual risk.
Trial Details
NCT Number NCT07199335
Lead Sponsor Massachusetts General Hospital
Collaborators: ViiV Healthcare, Fenway Community Health
Conditions HIV, Substance Use Disorder (SUD), Injection Drug Use
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov